-39%

est. 2Y upside i

HealthcareSeries B

Nourish is addressing the root cause of the chronic disease crisis through AI-powered, insurance-covered virtual nutrition care. We are tackling one of the most important problems in the world — our broken healthcare system. We are building a healthcare system that is patient-friendly, prioritizes lifestyle change, delivers outcomes, and lowers costs.

Rank

#1084

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Medium

Nourish presents a strong upside opportunity for a job seeker, driven by its leading position in the rapidly growing virtual nutrition care market.

Last updated: March 10, 2026

Bull (30%)+250%

Nourish leverages its extensive dietitian network (6,000+ RDs) and AI-powered platform to become the dominant player in virtual nutrition care, expanding into new chronic disease management pathways and securing major health plan partnerships. This drives revenue significantly above projections, justifying a $3.5B+ valuation (3.5x current) by 2028, potentially through an IPO or strategic acquisition.

Base (45%)+50%

Nourish continues its strong growth trajectory, maintaining its leadership in dietitian-led virtual care and expanding its patient base to over 500,000. It successfully navigates competitive pressures and regulatory changes, achieving a $1.5B valuation (1.5x current) through a later-stage funding round or a modest acquisition by 2028.

Bear (25%)-60%

Increased competition from large telehealth incumbents like Teladoc or Amwell, coupled with potential federal funding cuts to 'food-as-medicine' programs, stifles Nourish's growth and pricing power. This leads to a down round or acquisition at a significantly reduced valuation of $0.4B (0.4x current), severely impacting common stock value.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Funding Intensity

12%

Investors hold $115M in liquidation preferences ahead of common stock, representing 11.5% of the current $1.0B valuation.

Dilution Risk

moderate

As a Series B company, Nourish will likely undergo additional funding rounds, leading to further dilution for common shareholders.

Secondary Liquidity

limited

Accredited investors can buy pre-IPO stock in Nourish through platforms like EquityZen, indicating some limited secondary liquidity for existing shareholders.

Other — 1 role

View all 1 open roles at Nourish →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Nourish's data — designed to show you've done your homework.

  • 1

    “Given the 'medium' incumbent threat from broader telehealth players like Teladoc and Amwell, how does Nourish plan to further differentiate its specialized dietitian-led model and protect its market share?”

  • 2

    “The 2025 Impact Report highlights significant growth to 500,000+ patients and 6,000+ RDs. What are the key strategies for maintaining this growth trajectory and expanding into new market segments or chronic conditions over the next 2-3 years?”

  • 3

    “With a Series B funding round completed, how is Nourish thinking about the path to profitability and future funding needs, and what is the anticipated timeline or strategy for a potential liquidity event for employees?”

Community

Valuation Sentiment

Our model estimates -39% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.